Q-omics provides the consensus-scored ANKRD34B profile across patient tissues and cancer cell-line models. ANKRD34B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANKRD34B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ANKRD34B RNA expression shows 14,908 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where ANKRD34B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD34B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD34B survival associations across molecular data types. ANKRD34B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD34B RNA expression–survival associations across cancer types. High ANKRD34B expression shows unfavorable associations in MESO, ACC, COAD and UCEC, but favorable associations in CESC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANKRD34B RNA expression.
This table summarizes ANKRD34B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD34B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD34B shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, HNSC, BLCA and LUSC. The KIRC box plot shows higher ANKRD34B RNA expression in normal versus tumor tissue (log2 FC = −1.027, t-test p < 0.001).
This table shows molecular features associated with ANKRD34B in patient tissues and cancer cell lines. In patient samples, ANKRD34B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD34B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
